Vivek Ramaswamy Sells 200,800 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) major shareholder Vivek Ramaswamy sold 200,800 shares of the company's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $11.19, for a total transaction of $2,246,952.00. Following the completion of the sale, the insider now directly owns 38,426,381 shares in the company, valued at $429,991,203.39. This trade represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

• On Wednesday, June 4th, Vivek Ramaswamy sold 547,430 shares of Roivant Sciences stock. The shares were sold at an average price of $11.34, for a total transaction of $6,207,856.20.
• On Tuesday, May 6th, Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73.

Roivant Sciences Stock Performance

NASDAQ ROIV traded down $0.15 during mid-day trading on Monday, reaching $11.08. 3,586,965 shares of the stock were exchanged, compared to its average volume of 5,565,512. The business's 50 day moving average is $10.66 and its 200-day moving average is $11.00. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The company has a market capitalization of $7.91 billion, a P/E ratio of -73.86 and a beta of 1.16.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. The company had revenue of $7.57 million during the quarter, compared to analyst estimates of $62.17 million. During the same period in the prior year, the business posted ($0.23) EPS. Equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, May 28th.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock valued at $583,238,000 after purchasing an additional 156,527 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after purchasing an additional 2,404,232 shares in the last quarter. Patient Square Capital LP lifted its holdings in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after purchasing an additional 251,535 shares in the last quarter. Two Seas Capital LP lifted its holdings in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock valued at $120,285,000 after purchasing an additional 442,914 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Roivant Sciences by 3.8% during the first quarter. Invesco Ltd. now owns 9,880,526 shares of the company's stock valued at $99,695,000 after purchasing an additional 365,468 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.